Company Filing History:
3 out of 138 
1 out of 109 
1 out of 1,454 
Years Active: 2016-2023
Title: The Innovative Contributions of Ellen Olivia Gallimore
Ellen Olivia Gallimore is a notable inventor based in Slough, GB, recognized for her significant contributions to the field of pharmaceuticals. With a total of four patents to her name, she has made remarkable strides in developing compounds that modulate TNF activity, which are crucial in treating various human ailments.
Latest Patents
Ellen's latest patents include "Fused pentacyclic imidazole derivatives as modulators of TNF activity." This patent describes a compound that serves as a potent modulator of human TNF alpha activity, offering benefits in the treatment and prevention of autoimmune and inflammatory disorders, neurological and neurodegenerative disorders, pain and nociceptive disorders, cardiovascular disorders, metabolic disorders, ocular disorders, and oncological disorders. Another significant patent is "Fused tricyclic imidazole derivatives as modulators of TNF activity." This patent focuses on a series of fused tricyclic imidazole derivatives, particularly dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, which also act as potent modulators of human TNF alpha activity, addressing similar health issues.
Career Highlights
Throughout her career, Ellen has worked with prominent companies such as UCB Biopharma Sprl and UCB Biopharma Srl. Her work in these organizations has allowed her to contribute to groundbreaking research and development in the pharmaceutical industry.
Collaborations
Ellen has collaborated with notable colleagues, including Boris Kroeplien and Joanna Rachel Quincey. These partnerships have further enhanced her innovative efforts and expanded her impact in the field.
Conclusion
Ellen Olivia Gallimore's work exemplifies the importance of innovation in addressing complex health challenges. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.